荣昌生物:目前RC48在海外的临床试验正按计划推进中

蓝鲸财经
Sep 17

蓝鲸新闻9月17日电,荣昌生物(688331.SH)在业绩说明会上表示,公司2021年与美国西雅图基因公司(现被美国辉瑞公司收购,Pfizer Inc.)达成一项全球独家许可协议,公司授权维迪西妥单抗(代号:RC48)在荣昌生物区域(即除日本、新加坡以外的其他亚洲地区)以外地区的全球开发和商业化权益。目前,RC48在海外的临床试验正在由Pfizer按计划推进中。在国际化进程中,面临的主要挑战包括...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10